Assembly Biosciences Inc (ASMB) Q3 2016 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q3 2016 10-Q quarterly report on Nov 9, 2016 for the quarter ended Sep 30, 2016.

AI summary of MD&A and risk factor updates

Quarterly revenue: $0, with no FDA-approved products or product sales revenue
Operating loss: $32.7M net loss for nine months ended September 30, 2016, versus $20.7M YoY
Worst-performing program: HBV-cure R&D expense increased $2.6M quarterly, versus $1.0M for microbiome
Operating cash use: $23.8M for nine months, versus $13.2M YoY
Outlook: existing cash, equivalents and marketable securities fund operations at least twelve months, additional capital expected thereafter

No new or changed risk factors identified, section carries forward prior 10-K risks
Clinical development risk: ABI-H0731 in Phase 1a/1b, while ABI-M101 remains late preclinical
Regulatory risk: FDA approval requires extensive evidence and may impose post-marketing studies or restrict labeling
Competitive risk: HBV and CDI landscapes rapidly changing as competing clinical and commercial products emerge
Financial risk: accumulated deficit $196.7 million, with additional financing required after resources funding at least twelve months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.